DelMar Pharmaceuticals Announces Presentation at the European Association of Neuro-Oncology (EANO) Annual Meeting in October 2016 July 21, 2016
DelMar Pharmaceuticals Presents Phase I/II GBM Clinical Trial Data and Outlines Future Clinical Development Plans at ASCO 2016 Annual Meeting June 6, 2016
DelMar Pharmaceuticals Announces Successful Completion of End-of-Phase 2 Meeting with FDA on VAL-083 for the Treatment of Refractory Glioblastoma Multiforme May 25, 2016
DelMar Pharmaceuticals Announces Reverse Stock Split in Preparation for Proposed Senior Exchange Uplisting May 19, 2016
DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2016 Financial Results and Corporate Update May 13, 2016
DelMar Pharmaceuticals, Inc. Announces $5.6 Million Private Placement Of Preferred Shares May 5, 2016
DelMar Pharmaceuticals Updates Ongoing Phase I/II Refractory GBM Clinical Trial with VAL-083 at American Association Cancer Research (AACR) Annual Meeting April 19, 2016
